TFG
VRTX icon

Team Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Team Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27
Closed -$12.1K – 246
2026
Q1 		$12.1K Hold
27
– – 0.01% 191
2025
Q4 		$12.2K Hold
27
– – 0.01% 178
2025
Q3 		$10.6K Hold
27
– – ﹤0.01% 185
2025
Q2 		$12K Buy
+27
New +$12.4K 0.01% 166

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Team Financial Group's VRTX Position: Q2 2026 in Review

Team Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 27 shares — an estimated $12.1K sold.

Team Financial Group first reported a position in VRTX in Q2 2025 and held it in 4 quarters. The position peaked at $12.2K in Q4 2025. 302 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Team Financial Group reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Team Financial Group sold 27 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.1K.
  • Team Financial Group first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Team Financial Group's Vertex Pharmaceuticals position peaked at $12.2K in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Team Financial Group's 13F filing for Q2 2026, filed 13 Jul 2026.